GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » EBIT

The Oncology Institute (The Oncology Institute) EBIT : $-66.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute EBIT?

The Oncology Institute's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-17.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-66.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. The Oncology Institute's annualized ROC % for the quarter that ended in Mar. 2024 was -63.50%. The Oncology Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -98.28%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. The Oncology Institute's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -76.49%.


The Oncology Institute EBIT Historical Data

The historical data trend for The Oncology Institute's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute EBIT Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -2.64 -14.47 -11.28 3.99 -76.33

The Oncology Institute Quarterly Data
Sep18 Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.51 -14.13 -14.59 -20.31 -17.90

Competitive Comparison of The Oncology Institute's EBIT

For the Medical Care Facilities subindustry, The Oncology Institute's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's EV-to-EBIT falls into.



The Oncology Institute EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Oncology Institute  (NAS:TOI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

The Oncology Institute's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-71.888 * ( 1 - 0% )/( (109.83 + 116.573)/ 2 )
=-71.888/113.2015
=-63.50 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

The Oncology Institute's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-71.616/( ( (40.052 + max(31.662, 0)) + (38.411 + max(35.614, 0)) )/ 2 )
=-71.616/( ( 71.714 + 74.025 )/ 2 )
=-71.616/72.8695
=-98.28 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(42.36 + 13.678 + 4.049) - (16.555 + 2.751 + 9.119)
=31.662

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.76 + 11.554 + 4.678) - (22.127 + 3.225 + 14.026)
=35.614

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

The Oncology Institute's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-66.927/87.500
=-76.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Oncology Institute EBIT Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


The Oncology Institute (The Oncology Institute) Business Description

Traded in Other Exchanges
N/A
Address
18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Executives
Havencrest Healthcare Partners, L.p. 10 percent owner 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah officer: Chief Financial Officer, other: Principal Financial Officer C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively director, officer: Chief Executive Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle officer: Chief Operating Officer 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch director, officer: Executive Chairman C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos officer: Chief Medical Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit officer: Chief Accounting Officer, other: Principal Accounting Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal director 44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian 10 percent owner C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara director C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201